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Haploidentical hematopoietic stem cell transplantation (HSCT) performed using bone marrow (BM) grafts
and post-transplantation cyclophosphamide (PTCy) has gained much interest for the excellent toxicity proﬁle
after both reduced-intensity and myeloablative conditioning. We investigated, in a cohort of 40 high-risk
hematological patients, the feasibility of peripheral blood stem cells grafts after a treosulfan-melphalan
myeloablative conditioning, followed by a PTCy and sirolimus-based graft-versus-host disease (GVHD) pro-
phylaxis (Sir-PTCy). Donor engraftment occurred in all patients, with full donor chimerism achieved by day
30. Post-HSCT recovery of lymphocyte subsets was broad and fast, with a median time to CD4 > 200/mL of 41
days. Cumulative incidences of grade II to IV and III-IV acute GVHD were 15% and 7.5%, respectively, and were
associated with a signiﬁcant early increase in circulating regulatory T cells at day 15 after HSCT, with values <
5% being predictive of subsequent GVHD occurrence. The 1-year cumulative incidence of chronic GVHD was
20%. Nonrelapse mortality (NRM) at 100 days and 1 year were 12% and 17%, respectively. With a median
follow-up for living patients of 15 months, the estimated 1-year overall and disease-free survival (DFS) was
56% and 48%, respectively. Outcomes were more favorable in patients who underwent transplantation in
complete remission (1-year DFS 71%) versus patients who underwent transplantation with active disease
(DFS, 34%; P ¼ .01). Overall, myeloablative haploidentical HSCT with peripheral blood stem cells (PBSC) and
Sir-PTCy is a feasible treatment option: the low rates of GVHD and NRM as well as the favorable immune
reconstitution proﬁle pave the way for a prospective comparative trial comparing BM and PBSC in this speciﬁc
transplantation setting.
 2015 American Society for Blood and Marrow Transplantation.edgments on page 1513.
quests: Dr. Fabio Ciceri, Hematology and
faele Scientiﬁc Institute, via Olgettina 60,
r.it (F. Ciceri).
eri, Lara Crucitti, and Georgia Levati:
ilan, Italy.
15.04.025
ty for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a potentially curative therapy for many malignant
and nonmalignant hematological disorders [1]. Although
HLA-identical siblings or HLA-matched unrelated donors
(MUD) are considered the ideal sources of hematopoietic
stem cells, many patients lack timely access to a suitable
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disease. A promising alternative stem cell source is the HLA-
haploidentical mismatched family donor who is readily
available for nearly all patients [2].
Historically, transplantation across the major HLA barrier
has been hampered by alloreactivity, manifested in the early
attempts as a high incidence of severe graft-versus-host
disease (GVHD) and graft rejection [3]. Subsequent strate-
gies focusing on stringent ex vivo T cell depletion of the graft,
often coupled with intensive preparative regimens, proved
effective in preventing GVHD but at the expense of delayed
immune reconstitution and high rate of nonrelapsemortality
(NRM) [4,5]. In this setting, cell-based strategies to boost
post-transplantation immune recovery could efﬁciently
abate infectious mortality [6,7] but are, at present, difﬁcult to
perform outside highly specialized centers.
In recent years, several groups have devised successful
approaches to perform T cellereplete transplantation, even
in the full haplotype-mismatched setting. Among other ap-
proaches [8-10], that which has gained the most interest has
been the use of high-dose post-transplantation cyclophos-
phamide (PTCy) as in vivo T celleallo-depleting agent [11,12].
This approach has demonstrated promising results, including
acceptable rates of NRM and severe GVHD in single- and
multi-institution phase II trials and achieving outcomes
equivalent to those of HSCT performed using HLA-identical
donors or MUD [13].
Haploidentical HSCT with PTCy (haplo-PTCy), as origi-
nally devised by Luznik et al., relied on nonmyeloablative
conditioning and bone marrow (BM) as graft source [14].
Although associated with low rates of GVHD and NRM, such
transplantation strategy was somehow limited by relatively
high relapse rates. Recently, different groups have reported
encouraging outcomes using peripheral blood stem cell
(PBSC) grafts [15-17], myeloablative conditioning regimens
[18], or a combination of both [19]. Thus, although different
conditioning regimens and stem cell sources have been
tested in the context of haplo-PTCy, reported GVHD pro-
phylaxis regimens have relied only on calcineurin inhibitors
(CNIs) to date. Current evidence suggests that CNIs nega-
tively affect regulatory T cells (Treg) [20], which are needed
to establish appropriate peripheral tolerance after trans-
plantation and to prevent GVHD [21]. In contrast to CNIs,
sirolimus is able to foster post-transplantation Treg recovery
[10,22], a property also described for PTCy in the absence of
CNIs [23,24]. Besides promoting Treg expansion [25], siroli-
mus may have several additional advantages over other
immunosuppressive agents, thanks to its pleiotropic effects,
comprising inhibition of antigen presentation and dendritic
cell maturation [26-28], antiﬁbrotic activity [29,30], antiviral
properties [31], and, most importantly, direct antitumor ac-
tivity [32-35]. Therefore, in the present report, we investi-
gated whether the combination of a PBSC graft, intensiﬁed
myeloablative conditioning, and postgraft sirolimus instead
of tacrolimus could help increase the feasibility, and possibly
also the therapeutic index, of haplo-PTCy.PATIENTS AND METHODS
Patients
A cohort of 40 consecutive patients with high-risk hematological
malignancies at the San Raffaele Haematology and Bone Marrow Trans-
plantation unit received a myeloablative regimen with sirolimus-PTCy
(Sir-PTCy) between November 2012 and July 2014. All patients were
treated according to current institutional programs upon written informed
consent for transplantation procedures and biological sampling. Patients
were considered to be in complete remission if disease activity could not bedocumented by BM evaluation or imaging, depending on the underlying
disease. All other patients not falling within this deﬁnition were categorized
as having active disease. Additionally, patients were stratiﬁed by status at
the time of transplantation according to the revised disease risk index (DRI)
deﬁned by Armand et al. [36]. Because the DRI has been validated only for
patients at ﬁrst transplantation, we considered patients with a previous
allogeneic HSCT in a distinct category. Comorbidities at time of trans-
plantation were evaluated according to the comorbidity-age index [37], and
predicted natural killer (NK) cell alloreactivity according to the model
developed by Ruggeri et al. [38].
HLA Matching
Donors were patients’ relatives, deﬁned as biological parents, siblings,
children, or cousins. HLA compatibility among donor-recipient pairs was
assessed by 10 loci molecular typing (HLA-A, -B, -C, -DRB1, and -DQB1) at
the allelic level. Whenever possible, haplotype segregation was determined
based on the typing of ﬁrst-degree relatives.
Conditioning Regimen and GVHD Prophylaxis
Myeloablative conditioning consisted of treosulfan (14 g/m2/day) on
days 6 to 4, ﬂudarabine (30 mg/m2/day) on days 6 to 2, and
melphalan (70 mg/m2/day) on days 2 and 1, followed by T cellereplete
granulocyte colonyestimulating factor (G-CSF)emobilized PBSCs. Post-
grafting immunosuppression consisted of PTCy (50 mg/kg/day) on days 3
and 4, followed bymycophenolate mofetil (MMF,10 mg/kg three times daily
orally or i.v.) and sirolimus (orally, monitored 2 times each week tomaintain
a target therapeutic plasma level of 8 to 14 ng/mL during the ﬁrst 2 months
after transplantation, thereafter of 5 to 8 ng/mL until discontinuation). In the
absence of GVHD or disease relapse, tapering of MMF was initiated after
engraftment, starting from day 20 to achieve discontinuation by day 30.
Sodium 2-sulfanylethanesulfonate (mesna) and i.v. hydration were admin-
istered for uro-protection.
Stem Cell Source
Donors were mobilized by the subcutaneous administration of G-CSF for
5 to 6 days at 10 mg/kg/day. PBSCswere collected by leukapheresis to achieve
a target stem cell dose of 4 to 8  106 CD34þ cells per kg of patient body
weight.
Supportive Care
Antimicrobial prophylaxis and treatment of infectious complications
were administered per the institutional guidelines, following international
recommendations [39-41]. All patients received, from the ﬁrst day of con-
ditioning, acyclovir, levoﬂoxacin, and voriconazole. Cytomegalovirus (CMV)
reactivationsweremonitoredweekly in peripheral blood plasma samples by
quantitative PCR. A pre-emptive treatment with gancyclovir or foscarnet
was started when CMV DNA copy number was more than 1000 copies/mL or
increased more than .5 log in peripheral blood plasma. Epstein-Barr virus
(EBV) was monitored on plasma samples every 2 weeks by PCR and ritux-
imab (375 mg/m2) was administered as pre-emptive treatment in case of
high (>1000 copies/mL) or rising DNAemia in 2 consecutive determinations;
if possible, this was accompanied by reduction of immunosuppressive
therapy. A regular monitoring of human herpes virus-6 (HHV-6) DNA in
plasma, using a real-time PCR assay, was performed weekly within the ﬁrst
100 days after HSCT, and antiviral therapy with either foscarnet or gancy-
clovir was started in case of possibly HHV6-related clinical manifestations.
Engraftment, Chimerism, and Relapse Detection
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with neutrophil counts  .5  109/L after transplantation, and platelet
engraftment was deﬁned as platelet counts  20  109/L in the absence of
transfusions during the preceding 7 days. Post-transplantation disease
follow-up consisted of monthly BM evaluations for the ﬁrst 3 months after
transplantation and then 2 times each year. Additional BM evaluations were
performed 4.5 and 9 months after HSCT in patients with high-risk acute
leukemia. We assessed donor-recipient chimerism on unfractionated BM
aspirate samples with a commercial assay based on quantitative PCR
detection of insertion/deletion polymorphisms, all outside the HLA complex
(AlleleSEQR Chimerism Assay, Celera Genomics, Rockville, MD). In the cases
for which informative patient-speciﬁc polymorphisms were not available,
short-tandem repeats analysis (AmpFISTR Proﬁler Plus PCR Kit; Applied
Biosystem, Carlsbad, CA) was used. Patients were considered fully chimeric
if their unfractionated BM samples were  5% host or  95% donor,
depending on the technique used.
In case of acute leukemia relapse, deﬁned as the presence of >5% of
leukemic blasts in the BM aspirate, eventual genomic loss of the mis-
matched HLA was performed either by low-resolution typing or by allele-
speciﬁc quantitative PCR, as previously described [42,43]. In case of
Table 1
Patient, Donor, and Transplantation Characteristics
Characteristic Value
No. of patients 40
Age, median (range), yr 55 (21-78)
Gender
Male 23
Female 17
Disease
AML 22 (CR1 ¼ 3, CR > 1 ¼ 3, rel/ref ¼ 16)
ALL 5 (CR1 ¼ 2, CR > 1 ¼ 1, rel/ref ¼ 2)
MDS 1 (ref ¼ 1)
CML 1 (blast crisis ¼ 1)
HD 6 (CR > 1 ¼ 3, SD/PD ¼ 3)
NHL 5 (CR1 ¼ 1, CR > 1 ¼ 2, PR ¼ 1, PD ¼ 1)
DRI
Low 0
Intermediate 12
High 13
Very high 6
Previous allogeneic HSCT 9
Days from diagnosis to
allogeneic HSCT,
median (range)
461 (100-2896)
Comorbidity-age index
0 1
1-2 10
3 28
Not evaluable 1
HLA mismatches
5 34
3-4 4
1-2 2
Predicted NK alloreactivity 13
Graft composition
CD34þ cells  106/kg,
median (range)
6.02 (4.15-8.02)
CD3þ cells  108/kg,
median (range)
2.22 (1.05-4.83)
CMV status (donor/recipient)
Positive/positive 19
Negative/positive 16
Positive/negative 1
Negative/negative 4
AML indicates acute myeloid leukemia; CR, complete remission; rel/ref,
relapsed/refractory; ALL, acute lymphoblastic leukemia; MDS, myelodys-
plastic syndrome; CML, chronic myeloid leukemia; HD, Hodgkin’s disease;
SD, stable disease; PD, progressive disease; NHL, non-Hodgkin lymphoma;
NK, natural killer.
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leukemic cells were ﬂuorescent activated cell sorterepuriﬁed and conﬁr-
matory genomic HLA typing was performed on sorted cells.
Immune Reconstitution
We studied immune reconstitution dynamics by ﬂow cytometry. Data
were analyzed with the FCS Express software (De Novo Software, Glendale,
CA). Absolute cell counts were determined on the CD45bright/SSClow
population with ﬂuorochrome-conjugated monoclonal antibodies to CD3,
CD4, CD8, CD16 and CD56, TCRab, TCRgd, and TrueCount beads (Beckman
Coulter, Brea, CA). B cell reconstitutionwas deﬁned as B cell counts  1 cells/
mL. In a group of patients, selected based on sample availability, we
analyzed the frequencies of circulating CD4þ recent thymic emigrants
(RTEs), deﬁned as CD45RAþCD62LþCD95CD31þ and CD4þ Treg, deﬁned as
CD25þCD127Foxp3þ. Samples were acquired on a Fortessa cytometer
(Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo software
version 9.8 (Tree Star Inc., Ashland, OR).
GVHD Grading and Treatment
Clinical diagnosis and grading of acute GVHD (aGVHD) were made ac-
cording to the consensus criteria [44,45]. Chronic GVHD (cGVHD) diagnosis
and grading were based on the National Institutes of Health consensus
criteria [46,47]. GVHD was treated per institutional protocols, considering
the European Society for Blood and Marrow Transplantation-European
Leukemia Net recommendations [48].
Statistical Analysis
Outcomes are reported as of November 2014. Probabilities of overall
survival (OS) and disease-free survival (DFS) were estimated using the
Kaplan-Meier method, and cumulative incidences (CI) were provided. CI of
NRM, relapse, aGVHD, and cGVHD were computed to take into account the
presence of competing risks. Speciﬁcally, in calculating the CI rates of NRM,
the competing risk was relapse; when calculating relapse, the competing
risk was NRM. When calculating neutrophil and platelet recovery, the
competing risk was death. For aGVHD and cGVHD, the competing risks were
relapse and death. All patients were considered evaluable for aGVHD anal-
ysis, and those who had a documented engraftment and a follow-up >100
days were evaluated for cGVHD. P values were considered signiﬁcant if <
.05. Statistical analyses were performed with SPSS version 13.0 and R
version 2.12.2 (R Project for Statistical Computing, http://www.r-projec-
t.org/), package “cmprsk” [49]. Statistical analyses of immune reconstitution
data were performed with Prism 5 (GraphPad Software, Carlsbad, CA).
RESULTS
Patients and Graft Characteristics
Patients, donor, and graft characteristics are provided in
Table 1. All subjects had high-risk hematologic malignancies,
with the most common diagnosis being acute myeloid leu-
kemia (55%). A total of 25 patients (62.5%) had active disease
at transplantation, whereas 15 (37.5%) were in hematologic
remission. Twelve patients (30%) received a prior autologous
HSCT and 9 patients (22.5%) received a prior allogeneic HSCT
(4 HLA identical, 3 MUD, and 2 cord blood transplantations).
Nineteen (61%) of the 31 patients who underwent haplo-
PTCy as ﬁrst allogeneic transplantation scored high/very
high according to DRI, 12 patients (39%) scored intermediate,
and no patient had a low disease score. Eleven (27.5%) pa-
tients received the transplant from siblings, 5 from parents,
and 22 from sons or daughters. The majority of donor-
recipient pairs (85%) were mismatched for 5 of 10 HLA loci.
Themedian age of patients was 55 years (range, 21 to 78) and
median age of donor was 36 years (range, 20 to 68).
Engraftment and Chimerism
PBSCs were collected by leukapheresis and infused
without ex vivo manipulation. Median CD34þ and CD3þ cell
doses were 6.02106/kg (range, 4.15 to 8.02) and 2.22108/
kg (range, 1.05 to 4.83), respectively. The conditioning
regimen induced absolute grade 4 neutropenia in all pa-
tients. Median time to neutrophil counts > .5  109/L was 18
days (range,13 to 45 days) and to platelet counts> 20109/L
was 16 days (range, 9 to 100 days) (Table 2). At 30 days afterHSCT, neutrophil engraftment occurred in 100% of the pa-
tients and platelet engraftment in 82.5% (Figure 1A,B). At ﬁrst
BM evaluation, performed 30 days after HSCT, 34 of 36
evaluable patients (94%) presented full-donor chimerism,
whereas the remaining 2 patients displayed hematological
disease persistence. No case of primary graft failure or
persistent mixed chimerism was documented. Median time
of discharge after transplantation was 32 days (range, 20
to 187).Transplantation-Related Complications and Infections
Transplantation-related complications and infections are
outlined in Table 2. Sirolimus-related posterior reversible
encephalopathy syndrome developed in 1 patient and
resolved with sirolimus discontinuation. Severe mucositis
occurred in 6 patients (15%). No case of hepatic veno-
occlusive disease or HSCT-associated thrombotic micro-
angiopathy was observed. Five patients (12%) developed
severe bacterial infections: 2 gram-negative sepsis
(1 carbapenemase-producing Klebsiella pneumonia, 1 Steno-
trophomonas maltophilia), 1 pulmonary tuberculosis, and in
Table 2
Complications and Infections
Complications and Infections n
Mucositis grade III 6
PRES 1
Hemorrhagic cystitis
Mild 4
Requiring treatment 5
Severe bacterial infections
G-sepsis 2
Tbc 1
Unknown etiology 2
Viral infections
CMV reactivation 22
EBV reactivation 6
HHV6 positivity 25
Other 1 (enterovirus)
IFI
Before HSCT 11 (possible ¼ 5, probable ¼ 6)
After HSCT 5 (possible ¼ 1, probable ¼ 4)
PRES indicates posterior reversible encephalopathy syndrome; G, gram-
negative; Tbc, tuberculosis.
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tiﬁed. Hemorrhagic cystitis developed in 9 patients (22%),
with concomitant BK virus positivity in 7 patients (78%), 1
related to JC virus and the last associated with previous
radiotherapy. Five patients required treatment with bladder
irrigation and/or analgesics, and cystitis resolved in all 9
patients. CMV reactivation occurred in 22 of 35 patients
(63%) who were at high risk of reactivation (donor seropos-
itive/seronegative, recipient seropositive). Six patients, all
receiving transplants from seropositive donors, developed
CMV disease (2 colitis, 3 pneumonia and 1 encephalitis), and
the median time to CMV reactivation was 33 days (range, 9
to 100). EBV DNAemia was detected in 6 patients (15%), of
whom 4 required pre-emptive treatment with rituximab. No
case of EBV post-transplantation lymphoproliferative disor-
der was observed. One patient developed enterovirus-
related hepatitis and myocarditis. Twenty-ﬁve patients
(62.5%) developed HHV6 positivity (15 on peripheral blood, 7
on gut biopsies, 2 on cerebrospinal ﬂuid, 1 on bron-
choalveolar lavage) and 15 (60%) received foscarnet. Eleven
patients (27%) had invasive fungal infection (IFI) before
transplantation, but importantly, IFI was not a cause of
mortality for any of these patients after HSCT. Of the
remaining 29 patients without IFI before HSCT, 5 patients
developed a possible (n ¼ 1) or probable (n ¼ 4) IFI afterFigure 1. Cumulative incidence of (A) neutrophiltransplantation. Importantly, all infectious events occurred
within the ﬁrst 6 months after transplantation, before im-
mune suppression discontinuation, which occurred at a
median of 28 days after transplantation (range, 24 to 58) for
MMF and a median of 201 days (range, 25 to 461) for
sirolimus.
Kinetics of Immune Reconstitution
The median lymphocyte counts, performed at 30, 90, 180,
and 365 days after HSCT, are depicted in Figure 2. All
evaluable patients achieved rapid T cell reconstitution
(Figure 3A-C), showing median cell counts at day 30 after
HSCT of 338 CD3þ cells/mL (range, 5 to 2564 cells/mL). The T
cell repertoire was skewed toward CD8þ cells, as frequently
observed after allogeneic HSCT. The median time to CD4þ
> 200/mL was 41 days (range, 21 to 107). CD31 expression on
CD4þ naïve T cells was analyzed to quantify RTEs. All patients
had a signiﬁcantly higher proportion of circulating RTEs at
day 30 and 180 compared with their pre-HSCT levels, sug-
gesting that thymic function was not impaired, and possibly
even improved, after HSCT (Figure 3D). NK cell reconstitution
was similarly fast (Figure 2E), withmedian cell counts on day
30 after HSCT of 19 CD3CD56þCD16þ cells per mL (range,
0 to 417 cells/mL). Median time to B cell reconstitution was
41 days (range, 24 to 278) (Figure 2F).
GVHD
The CI of grade II to IV and III and IV acute GVHD (aGVHD)
at day 100 after HSCT were 15% and 7.5%, respectively
(Figure 3A and Table 3). There was no signiﬁcant correlation
between the number of infused CD3þ cells and aGVHD: the
CI rates of grade II to IV aGVHDwere 15% and 20% for patients
receiving less or more than the median number of CD3þ cells
(2.22 108/kg), respectively (P¼ .12). Tregs have been shown
to play a role in GVHD prevention by PTCy both in preclinical
models and in humans [23,24]. To verify the hypothesis that
the combination of PTCy and sirolimus could promote Treg
expansion after transplantation, we closely evaluated Treg
dynamics in our cohort of patients. Indeed, we found that
circulating donor-derived Tregs were signiﬁcantly expanded
at day 15 after transplantation, compared with both leuka-
pheresis samples and healthy controls (Figure 3B). Of notice,
patients not experiencing aGVHD displayed signiﬁcantly
higher percentages of circulating Tregs at day 15 after HSCT
compared with those who subsequently developed aGVHD
(Figure 3C). Thirty-one patients were evaluable for cGVHD.engraftment and (B) platelet engraftment.
Figure 2. Immune reconstitution. Absolute counts of (A) CD3þ T cells, (B) CD8þ T cells, and (C) CD4þ T cells. (D) Flow-cytometric quantiﬁcation of circulating recent
thymic emigrants (expressed as percent of CD31þ cells on CD4þ naïve T cells) before (pre), and after 30 and 180 days from transplantation. (E) Absolute counts of
CD56þCD16þCD3 NK cells. (F) Absolute counts CD19þ B cells circulating in peripheral blood of patients at different time points, namely 30, 90, 180, and 365 days
after transplantation. Grey shadows denote normal reference values for each subset analyzed. * P < .05; *** P < .001.
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whereas the CI of severe cGVHD was 5.1% (Figure 3D). The
median time of onset of cGVHD was 141 days from HSCT
(range, 83 to 408).
NRM
The CI of NRM at day 100 and at 1 year was 12% and 17%,
respectively, with most of the events occurring in the ﬁrst 3
months after transplantation (median, day 63) (Figure 4).
Infections were the primary cause of death in 6 patients
(15%): 2 sepsis, 3 pneumonia (2 caused by CMV, 1 by Myco-
bacterium tuberculosis), and 1 hepatitis/myocarditis. One
patient died from complications associated with aGVHD and
concomitant CMV pneumonia. Notably, only 1 patient who
underwent Sir-PTCy as second transplantation died of NRM,
with the CI of NRM at 100 days and 1 year for second
transplantation being 11%.
Relapse
Relapse incidence was 35% 1 year after HSCT (Figure 5A).
In the subgroup of patients affected by acute leukemia, we
documented 11 cases of relapse after HSCT (Figure 5B): 3
(27% of relapses) were due to immune escape leukemic
variants characterized by selective genomic loss of the HLA
haplotype mismatched between patient and donor [50,51].
Of note, 1 of the HLA-loss relapses was observed, for the ﬁrst
time to our knowledge, in a patient affected by acute
lymphoblastic leukemia. In line with previous reports
[10,43], HLA-loss leukemia relapses occurred at a median of
300 days after HSCT (range, 255 to 414), whereas “classical”relapses at a median of 94 days after HSCT (range, 37 to 197).
Among patients with acute myeloid leukemia, no difference
in relapse incidence was observed according to the presence
or absence of predicted NK alloreactivity in the graft-versus-
host direction (P ¼ .52).
Survival and DFS
With a median follow-up of over 15 months (range, 5 to
24 months, with 25% of living patients with a follow-up  12
months), the estimated 1-year probabilities of OS and DFS
were 56% and 48%, respectively (Figure 6A). DFS was 71% for
patients who underwent transplantation in remission and
34% for those patients who underwent transplantation with
active disease (P ¼ .01, Figure 6B). A total of 8 patients (32%)
with active disease at transplantationwere alive, and 6 (75%)
were alive and in remission at a median of 511 days after
transplantation. There was a trend towards longer DFS in
patients with more favorable DRI: 1-year DFS was 64% for
patients with intermediate DRI and 41% for patients with
high/very high DRI (P ¼ .07) (Figure 6C). Interestingly, pa-
tients who had relapsed after a previous allogeneic HSCT
displayed DFS superior to that of patients with high/very
high DRI (DFS at 1 year 42%).
DISCUSSION
In the present report, we present our investigational
experience on the combination of myeloablative condition-
ing, PBSC as stem cell source, and a CNI-free, sirolimus-based
GVHD prophylaxis in the context of haploidentical HSCTwith
PTCy. Our group demonstrated previously that a sirolimus-
Figure 3. GVHD. (A) Cumulative incidence of grade II to IV (dashed line) and grade III and IV (full line) aGVHD. (B) Frequency of regulatory T cells (deﬁned as
CD25þCD127FoxP3þ CD4þ T cells) circulating in the peripheral blood of patients at different time-points after transplant and compared with the frequency in both
healthy donors’ peripheral blood (HDs) and the leukapheresis product (LK) infused. (C) Comparison of Treg frequencies at day 15 in patients subsequently developing
or not aGVHD. (D) Cumulative incidence of overall (dashed line) and severe cGVHD (full line) classiﬁed according to NIH criteria. * P < .05; *** P < .01; ****P < .001. ns
indicates not signiﬁcant.
Table 3
Clinical Outcomes
Outcome Value
Follow-up of surviving patients, median (range), d 451 (140-728)
Engraftment
Time to neutrophil .5  109/L, median (range), d 18 (13-45)
Time to platelets 20  109/L, median (range), d 16 (9-100)
aGVHD, n
Grade II-IV 7
Grade III-IV 3
cGVHD, n
No 19
Minimal 2
Moderate 7
Severe 3
Day þ100 NRM, n 5
Overall NRM, n 7
Relapse, n
Overall 13
AL relapses 11/27
Classical 8/11
HLA-loss 3/11
Relapse-related death, n 10
Surviving, n 23
NRM indicates non-relapse mortality; AL, acute leukemia.
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plantation from haploidentical donors, but such approach
was limited by a relatively high NRM. Building on our pre-
vious experience, here we incorporated PTCy in the context
of a sirolimus-based GVHD prophylaxis. We hypothesized
that sirolimus and PTCy could synergize providing adequate
GVHD protection without excessively increasing the risk of
transplantation-related morbidities, especially in the setting
of patients with active disease and/or high DRI at trans-
plantation. We show that our modiﬁed haplo-PTCy platform
allows for a high rate of engraftment, with acceptable NRM
and GVHD rates, and encouraging remission rates. Impor-
tantly, despite the advanced age of the patients studied
(median age of 51 years, with 25% of patients older than 65),
the comorbidities (approximately two thirds of patients had
a comorbidity-age score of 3 or higher), and the relative poor
risk status of their malignancies (with the majority of pa-
tients having a high or very high DRI), NRM was 12% at 100
days and 17% at 1 year. This is in the range of NRM reported
for other PTCy-based approaches [15-17,52]. Thus, our results
indicate that intensiﬁcation of the conditioning regimen,
coupled with the use of PBSC, is feasible and does not
Figure 4. Cumulative incidence of NRM.
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recently reported [18,19,53].
An unexpected ﬁnding of this study was a high incidence
of viral reactivations. Although the overall mortality associ-
ated with these complications was limited, as evidenced by
the favorable NRM, it caused signiﬁcantmorbidity in patients
and often required aggressive antiviral therapy. Similar ob-
servations have been reported by 2 other independent
groups [19,54]. Such a high incidence of viral infections,
combined with the relatively low incidence of severe bac-
terial and mold infections, might depend, at least in part, on
PTCy’s mechanism of action. Preclinical studies have shown
that cyclophosphamide administered early after HSCT pref-
erentially kills activated, cycling alloreactive, predominantly
memory [55] T cells while sparing resting, nonalloreactive T
cells [56]. Given the high incidence of viral events, we might
speculate that alloreactivity, at least in the setting of PBSC
grafts, largely overlaps with cross reactivity of antiviral Tcells
[57]. However, despite the high incidence of viral reac-
tivations, the overall immune reconstitution proﬁle was
favorable, as evidenced by a median time to CD4þ > 200/mL
of only 41 days. This immune reconstitution kinetics was
faster compared with previous haplo-PTCy reports [52] and
could be related to the use of PBSC instead of BM grafts.Figure 5. Disease relapse. (A) Cumulative incidence of disease relapse in the entire p
curve represents cumulative incidence of relapses due to genomic loss of the mism
classical bone marrow relapses (full line).The incidences of acute and chronic GVHD were low and
similar to those reported previously for haplo-PTCy using
BM. Notably, the 15% CI of grade II to IV aGVHD we observed
is lower than those of other haplo-PTCy studies using PBSC as
graft source, which range from 30% to 53% at 1 year [15-
17,19]. In our setting, the low GVHD incidence might be, at
least in part, explained by a signiﬁcant early increase in
circulating regulatory T cells at day 15 after HSCT, possibly as
an effect of the combined activity of PTCy and sirolimus in
the absence of CNIs. Both agents have been reported to either
favor in vivo Treg expansion [10,25] or to selectively spare
this T cell subset [23,24]. Patients with active GVHD display
lower Treg frequencies compared with those without GVHD
[58,59]. Accordingly, we found that values of circulating
Tregs < 5% at day 15 after transplantation were predictive of
subsequent GVHD occurrence. Overall, these observations
suggest that replacement of standard CNI-based GVHD pro-
phylaxis with sirolimus helps prevent GVHD by a synergic
actionwith PTCy on the Treg pool early after transplantation.
Nevertheless, a crucial problem, especially in high-risk
patients, is relapse of the original disease. This has been
particularly relevant with PTCy, given the signiﬁcant rate of
disease relapse observed. Although in our study overall ef-
ﬁcacy is difﬁcult to assess given the small numbers, the
limited follow-up, and the poor disease risk of many patients,
survival seems promising. The 1-year OS of 56% and DFS of
48% are encouraging considering that approximately one
fourth of our patients had a prior allogeneic HSCT and one
half underwent transplantationwith active disease. Of the 25
patients who underwent transplantation in the presence of
active disease, the current DFS is 34%, which is nonetheless
comparable with the other published haplo-PTCy reports.
Yet, for patients who undergo transplantation with chemo-
resistant disease, relapse rates remains critical, despite
intensiﬁcation of the conditioning and the use of PBSC. In this
respect, an important concern about PTCy has been that
effective purging of alloreactive T cells might be the cause
of dampened graft-versus-tumor effect. Two observations
strongly argue against this hypothesis. First, we report on
several patients affected by chemoresistant disease, high or
very high DRI score, or who had relapsed after a previous
allogeneic HSCT, achieving sustained remissions. Secondly, a
strong indicator of an antileukemic effect mediated by
donor-derived T cells (despite effective PTCy-mediatedatient cohort. (B) Disease relapse in patients with acute leukemia; the dotted
atched HLA in leukemic cells (HLA-loss variants), over which are cumulated
Figure 6. Survival. (A) Kaplan-Meier estimates of disease-free (dashed line) and overall (full line) survival in the entire patient cohort. (B) DFS stratiﬁed according to
the disease status at transplantation. (C) DFS stratiﬁed according to the disease risk index.
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characterized by genomic loss of mismatched HLA, a mech-
anism we previously characterized for acute myeloid leuke-
mia [43,50,51], potentially favoring leukemia immune
evasion. Of note, here we have extended the spectrum of
hematological malignancies exploiting this mechanism by
reporting for the ﬁrst time an HLA-loss relapse in a patient
affected by acute lymphoblastic leukemia. Thus, the obser-
vation of HLA-loss relapses across different diseases suggests
that this mechanism of immune evasionmight be considered
as a surrogate marker of post-transplantation alloreactivity
directed against hematological malignancies.
Notably, 9 patients affected by acute leukemia included in
this study underwent Sir-PTCy haploidentical trans-
plantation as their second allogeneic HSCT (HSCT2). The
choice of donor for HSCT2 is controversial, and few studies
have evaluated the effect of donor change on transplantation
outcomes [60-63]. Indeed, in our cohort, 42% of patients
receiving haploidentical HSCT2 for leukemia relapse after
allogeneic transplantation could be rescued, with low rates
of NRM. Thus, although the patient number is too small to
draw a deﬁnite conclusion, our data suggest that hap-
loidentical HSCT using the Sir-PTCy platform is safe and
feasible for patients with acute leukemia who relapse after a
ﬁrst allogeneic HSCT.
In conclusion, our study, although limited by a small
number of patients with relatively short follow-up, suggests
that G-CSFemobilized PBSC is a viable alternative to BM as a
graft source for haplo-PTCy in high-risk diseases, and that
sirolimus-based GVHD prophylaxis allows valid GVHD pre-
vention in this context. The low rates of GVHD and NRM, as
well as the favorable immune reconstitution proﬁle, of our
Sir-PTCy platform pave the way for a prospective compara-
tive trial comparing BM and PBSC in this speciﬁc trans-
plantation setting.ACKNOWLEDGMENTS
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